EMA Withdrawn: Docetaxel Teva (docetaxel) — Teva B.V.

View source ↗

Summary

The EMA has withdrawn Docetaxel Teva, an injectable chemotherapy containing docetaxel, from the European market.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Adenocarcinoma
• Breast Neoplasms
• Carcinoma Non-small-cell Lung
• Head and Neck Neoplasms
• Prostatic Neoplasms
• Stomach Neoplasms

Drugs mentioned

• Docetaxel Teva (docetaxel)

Snippet

Status: Withdrawn. Therapeutic area: Head and Neck Neoplasms;Carcinoma, Non-Small-Cell Lung;Adenocarcinoma;Prostatic Neoplasms;Stomach Neoplasms;Breast Neoplasms. MAH: Teva B.V.. Decision date: 28/04/2020